EU regulator delays decision on Eisai-Biogen Alzheimer’s drug
The European Union’s medicines regulator has delayed it decision on Eisai and partner Biogen’s Alzheimer’s disease drug that was expected this week, the Japanese company said today.
If you are not happy with the results below please do another search
The European Union’s medicines regulator has delayed it decision on Eisai and partner Biogen’s Alzheimer’s disease drug that was expected this week, the Japanese company said today.
Stemirna Therapeutics has halted an early stage trial for a new cancer vaccine, two of its trial researchers said, in a fresh setback to the company, which has been grappling with tight funding.
The oral drug, to be sold under the brand name Duvyzat, is the first nonsteroidal drug approved to treat patients with all genetic variants of DMD, according to the FDA.
Yesterday the agency classified the recall of privately held Vyaire Medical’s respiratory support devices as most serious and said their use could cause major injuries or death.
“2023 was a banner year for MMC,” shared agency CEO Olga Fleming. “We artfully disrupted everything we touched, including our own brand. We exceeded all business goals, announced new partnerships with disruptive partners, and made significant investments in our people. In 2024 and beyond, we are focused on cultivating a place where people, companies, and brands can thrive to their fullest potential. With these executive appointments and promotions, we are steadfast in our commitment to exceed the loftiest workplace and business expectations, ushering in an era of unparalleled excellence.”
Tristan Bernard was elevated to account director, Jennifer Peckins to VP, account services, and Catherine Lawyer to senior research analyst. Bernard supports Peregrine’s clients with achieving their brand objectives at all stages of a product’s lifecycle. Peckins oversees multiple managed care client accounts spanning various disease states, including dermatology, immunology, pulmonology, rare disease, and oncology. Lawyer uses her knowledge of quantitative and qualitative research, business intelligence, and analytics to gather data-based insights and provide strategic recommendations to help clients boost the competitiveness of their products.
As part of a sweeping reorganization, Bayer Pharmaceuticals on Wednesday shuffled its leadership roster, which included the creation of a new unit and role changes.
The company stated that a combination of two of its cancer drugs failed to meet the main goals of a late-stage study evaluating it as an initial treatment for a type of lung cancer.
A new analysis from the Congressional Budget Office predicts that Novo Nordisk’s semaglutide will likely be subjected to Medicare’s Drug Price Negotiation Program under the Inflation Reduction Act.
Bayer predicted at least $1 billion in 2024 sales for prostate cancer drug Nubeqa, which is playing a bigger role for the drugmaker’s growth prospects after the failure of a promising anti-blood-clotting therapy.